



Novartis India Limited
Registered Office:
Inspire BKC
Part of 601 & 701
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

December 20, 2021

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding resignation of Chief Financial Officer of Novartis India Limited ('the Company / Novartis')

Dear Sir,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Mr. Felix Doss has tendered his resignation from the position of Chief Financial Officer of the Company, to pursue opportunities outside of Novartis. The resignation has been accepted and he will be relieved from his responsibilities at the end of business hours on December 31, 2021.

The Company is in the process of identifying a suitable successor and the same will be communicated to the stock exchange, once the position is filled up.

Kindly take note of the above on record.

Thanking you

Yours faithfully,

For Novartis India Limited

Monaz Noble
Non-Executive Director